Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02197104 · ClinicalTrials.gov registry record · Phase 2
Citocoline for Treatment in Fragile X-associated Tremor/Ataxia Syndrome
A Phase 2 study, sponsored by Rush University Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT02197104 is a Phase 2 study that has completed, run by Rush University Medical Center. The registered enrollment target is 10 participants.
The verdict
NCT02197104, a Phase 2 study, has completed, sponsored by Rush University Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The objective of this study is to determine if citocoline is effective for balance abnormalities and to stabilize cognitive decline in patients with fragile X-associated tremor ataxia syndrome. The study will test 1000mg twice daily of citocoline for 12 months in an open label pilot study, with study visits at baseline, 3, 6, and 12 months.
Interventions
- DRUG citocoline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2015-01 |
| Est. Completion | 2017-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02197104
The ClinicalTrials.gov registry entry for NCT02197104 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rush University Medical Center, which has 320 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which citocoline is the first listed.
NCT02197104 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02197104 about?
NCT02197104 is a clinical study titled "Citocoline for Treatment in Fragile X-associated Tremor/Ataxia Syndrome". The objective of this study is to determine if citocoline is effective for balance abnormalities and to stabilize cognitive decline in patients with fragile X-associated tremor ataxia syndrome. The study will test 1000mg twice daily of citocoline for 12 months in an open label pilot study, with stud...
What is the current status of trial NCT02197104?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2015-01. Estimated completion is 2017-01.
What interventions are being tested in trial NCT02197104?
The interventions under investigation include: citocoline (DRUG).
Who is sponsoring clinical trial NCT02197104?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.